The relationship between lipoprotein(a) and the complications of diabetes mellitus

Acta Diabetologica

Volumn 40, Issue 2, 2003, Pages 65-76

  Koschinsky, M L ^a   Marcovina, S M ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Apolipoprotein(a); Coronary heart disease; Diabetes mellitus; Diabetic complications; Lipoprotein(a)

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; LIPOPROTEIN A; METFORMIN; TROGLITAZONE;

ATHEROGENESIS; CLINICAL TRIAL; DISEASE ASSOCIATION; GLYCATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; VASCULAR DISEASE;

EID: 0038165072     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005920300007     Document Type: Review

References (115)

1. Pyorola K (1990) Diabetes and coronary artery disease: what a coincidence? J Cardiovasc Pharmacol 16:S8-S14
2. Gries FA, Koschinsky, T (1991) Diabetes and arterial disease. Diabetic Med 8:S82-S87
3. Jarrett RJ (1984) Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease - chicken, egg or neither? Diabetologia 26:99-102
4. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T (1987) Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors., Diabetologia 30:144-148
5. Berg K (1963) A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 59:362-382
6. Marcovina SM, Koschinsky ML (2000) Lipoprotein(a): structure, measurement and clinical significance. In: Rifai N, Warnick GR, Dominiczak MH (eds) Handbook of lipoprotein testing, 2nd edn. AACC Press, Washington DC, pp 345-385
7. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330:132-137
8. Lackner C, Cohen JC, Hobbs HH (1993) Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 2:933-940
9. Mooser V, Marcovina SM, White AL, Hobbs HH (1996) Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 98:2414-2424
10. Mooser V, Seabra MC, Abedin M, Landschulz KT, Marcovina S, Hobbs HH (1996) Apolipoprotein(a) kringle 4-containing fragments in human urine. J Clin Invest 97:858-864
11. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U (1989) Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary artery bypass patients. Arteriosclerosis 9:579-592
12. Kreuzer J, Lloyd MB, Bok D, Fless GM, Scanu AM, Lusis AJ, Haberland ME (1994) Lipoprotein(a) displays increased accumulation compared with low density lipoprotein in the murine artery wall. Chem Phys Lipids 67/68:175-190
13. Kojima S, Harpel PC, Rifkin DB (1991) Lipoprotein(a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 113:1439-1445
14. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM (1993) The proliferation of human smooth muscle cells is promoted by lipoprotein(a). Science 260:1655-1658
15. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC (1994) Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 370:460-462
16. Schachinger V, Halle M, Minners J (1997) Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J Am Coll Cardiol 30:927-934
17. Rand ML, Sangrar W, Hancock MA, Taylor DM, Marcovina SM, Packham MA, Koschinsky ML (1998) Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide, SFLLRN. Arterioscler Thromb Vasc Biol 18:1393-1399
18. Cheng SW, Ting AC, Wong J (1997) Lipoprotein(a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg 14:17-23
19. Peng DQ, Zhao SP, Wang JL (1999) Lipoprotein(a) and apolipoprotein E epsilon 4 as independent risk factors for ischemic stroke. J Cardiovasc Risk 6:1-6
20. Marcovina SM, Hegele RA, Koschinsky ML (1999) Lipoprotein(a) and coronary heart disease risk. Curr Cardiol Rep 1:105-111
21. Marcovina SM, Koschinsky ML (1998) Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 82:57-66
22. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE (1998) Lipoprotein(a) as a risk factor for ischemic heart disease: meta-analysis of prospective studies. Clin Chem 44:2301-2306
23. Danesh J, Collins R, Peto R (2000) Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation 102:1082-1085
24. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger, Utermann G, Willeit J (1999) Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck Study. Circulation 100:1154-1160
25. Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Kronenberg F, Abe A, Muhlberger, Schonitzer D, Utermann G (1996) Apolipoprotein(a) kringle IV repeat number predicts risk for coronary artery disease. Arterioscler Thromb Vasc Biol 16:713-719
26. Linden T, Taddei-Peters W, Wilhelmsen L, Herlitz J, Karlsson T, Ulstrom C, Wiklund O (1998) Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery. Atherosclerosis 137:175-186
27. Marcovina SM, Albers JJ, Wijsman E, Zhang Z, Chapman NH, Kennedy H (1996) Differences in Lp(a) concentrations and apo(a) polymorphs between black and white americans. J Lipid Res 37:2569-2585
28. Paultre F, Pearson TA, Weil HF, Tuck CH, Myerson M, Rubin J, Francis CK, Marx HF, Philbin EF, Reed RG, Berglund L (2000) High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 20:2619-2624
29. Hervio L, Girard-Globa A, Durlach A, Anglés-Cano E (1996) The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentrations of each of the apolipoprotein(a) isoforms and their affinity for fibrin. J Clin Invest 26:411-417
30. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr (1993) Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 91:443-447
31. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH (1992) Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 90:52-60
32. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler GH, Seitz C (1987) Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 80:458-465
33. Boerwinkle E, Menzel HJ, Kraft HG, Utermann G (1989) Genetics of the quantitative Lp(a) lipoprotein trait, III: contribution of Lp(a) glycoprotein phenotypes to normal lipid variation. Hum Genet 82:73-78
34. Scanu AM, Pfaffinger D, Lee JC, Hinman J (1994) A single point mutation (Trp 72-Arg) in human apo(a) kringle 4-37 is associated with a lysine binding defect in Lp(a). Biochim Biophys Acta 1227:41-45
35. Zysow BR, Lindahl GE, Wade DP, Knight BL, Lawn RM (1995) C/T polymorphism in the 5′ untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb Vasc Biol 15:58-64
36. Mooser V, Mancini FP, Bopp S, Petho-Schramm A, Guerra R, Boerwinkle E, Muller HJ, Hobbs HH (1995) Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma. Hum Mol Genet 4:173-181
37. Trommsdorff M, Kochl S, Lingenhel A, Kronenberg F, Delport R, Vermaak H, Lemming L, Klausen IC, Faergeman O, Utermann G, Kraft HG (1995) A pentanucleotide repeat polymorphism in the 5′ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in plasma. J Clin Invest 96:150-157
38. Suzuki K, Kuriyama M, Saito T, Ichinose A (1997) Plasma lipoprotein(a) levels and expression of the apolipoprotein(a) gene are dependent on the nucleotide polymorphisms in its 5′-flanking region. J Clin Invest 99:1361-1366
39. Angelin B (1997) Therapy for lowering lipoprotein(a) levels. Curr Opin Lipidol 8:337-341
40. Dieplinger H, Kronenberg F (1999) Genetics and metabolism of lipoprotein(a) and their clinical implications (Part 2). Wein Klin Wochenschr 111/2:46-55
41. Kronenberg F, Utermann G, Dieplinger H (1996) Lipoprotein(a) in renal disease. Am J Kidney Dis 27:1-25
42. Kronenberg F, Konig P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitlinger J, Pinter G, Utermann G, Dieplinger H (1995) Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6:110-120
43. Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, Graf H, König P (1993) Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 91:397-401
44. Zimmermann J, Herrlinger S, Pruy A, Wanner C (1997) Mechanism of high serum lipoprotein(a) in hemodialysis patients. J Am Soc Nephrol 8:260A
45. Hirata K, Kikuchi S, Saku K, Jimi S, Zhang B, Naito S, Hamaguchi H, Arakawa K (1993) Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with/without diabetes mellitus. Kidney Int 44:1062-1070
46. Auguet T, Sentí M, Rubies-Prat J, Pelegrí A, Pedro-Botet J, Nogués X, Romero R (1993) Serum lipoprotein(a) concentration in patients with chronic renal failure receiving hemodialysis: Influence of apolipoprotein(a) genetic polymorphism. Nephrol Dial Transplant 8:1099-1103
47. Bruckert E, Davidoff P, Grimaldi A, Truffert J, Giral P, Doumith R, Thervet F, De Gennes JL (1990) Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. JAMA 263:35-36
48. Haffner SM, Tuttle KR, Rainwater DL (1991) Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects. Diabetes Care 14:302-307
49. Couper JJ, Bates DJ, Cocciolone R, Magarey AM, Boulton TJ, Penfold JL, Ryall RG (1993) Association of lipoprotein(a) with puberty in IDDM. Diabetes Care 16:869-873
50. Salzer B, Stavljenic A, Jurgens G, Dumic M, Radica A (1993) Polymorphism of apolipoprotein E, lipoprotein(a), and other lipoproteins in children with type I diabetes. Clin Chem 39:1427-1432
51. Császár A, Dieplinger H, Sandholzer C, Karadi I, Juhasz E, Drexel H, Halmos T, Romics L, Patsch JR, Utermann G (1993) Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitus. Diabetologia 36:47-51
52. Klausen IC, Schmidt EB, Lervang HH, Gerdes LU, Ditzel J, Faergeman O (1992) Normal lipoprotein(a) concentrations and apolipoprotein(a) isoforms in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest 22:538-541
53. Gall MA, Rossing P, Hommel E, Voldsgaard AI, Andersen P, Nielsen FS, Dyerberg J, Parving HH (1992) Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy. Scand J Clin Lab Invest 52:513-521
54. Heller FR, Jamart J, Honore P, Derue G, Novik V, Galanti L, Parfonry A, Hondekijn JC, Buysschaert M (1993) Serum lipoprotein(a) in patients with diabetes mellitus. Diabetes Care 16:819-823
55. Purnell JQ, Marcovina SM, Hokanson JE, Kennedy H, Cleary PA, Steffes MW, Brunzell JD (1995) Levels of lipoprotein(a), apolipoproteinB, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial. Diabetes 44:1218-1226
56. Ramirez LC, Arauz-Pacheco C, Lackner C, Albright G, Adams BV, Raskin P (1992) Lipoprotein(a) levels in diabetes mellitus: relationship to metabolic control. Ann Intern Med 117:42-47
57. Neele DM, de Wit EC, Princen HM (1999) Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes. Diabetologia 42:41-44
58. Perez A, Carreras G, Caixas A, Castellvi A, Caballero A, Bonet R, Ordonez-Llanos J, de Leiva A (1998) Plasma lipoprotein(a) levels are not influenced by glycemic control in type I diabetes. Diabetes Care 21:1517-1520
59. Torres-Tamayo M, Perez-Pasten LE, Barron-Uribe C, Hermida-Guttierre, Zamora-Gonzalez J, Cardoso-Saldana G, Posadas-Romero C (1998) Improved metabolic control does not change plasma lipoprotein(a) levels in adolescents with type I diabetes mellitus. Arch Med Res 29:307-312
60. Kronenberg F, Auinger M, Trenkwalder E, Irsigler K, Utermann G, Dieplinger H (1999) Is apolipoprotein(a) a susceptibility gene for type I diabetes mellitus and related to long-term survival? Diabetologia 42:1021-1027
61. Luo DF, Bui MM, Muir A, Maclaren NK, Thomson G, She JX (1995) Affected-sib-pair mapping of a novel susceptibility gene to insulin-dependent diabetes mellitus (IDDM8) on chromosome 6q25-27. Am J Hum Genet 57:911-919
62. Lindahl G, Gersdorf E, Menzel HJ, Duba C, Cleve H, Humphries S, Utermann G (1989) The gene for the Lp(a)-specific glycoprotein is closely linked to the gene for plasminogen on chromosome 6. Hum Genet 81:149-152
63. Levitsky LL, Scanu AM, Gould SH (1991) Lipoprotein(a) levels in black and white children and adolescents with IDDM. Diabetes Care 14:283-287
64. Haffner SM, Morales PA, Stern MP, Gruber KK (1992) Lipoprotein(a) concentrations in NIDDM. Diabetes 41:1267-1272
65. Jenkins AJ, Steele JS, Janus ED, Santamaria JD, Best JD (1992) Plasma apolipoprotein (a) is increased in type 2 (noninsulin-dependent) diabetic patients with microalbuminuria. Diabetologia 35:1055-1059
66. Rainwater DL, MacCluer JW, Stern MP, VandeBerg JL, Haffner SM (1994) Effects of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size. Diabetes 43:942-946
67. Duell PB, Hagemenas F, Connor WE (1994) The relationship between serum lipoprotein(a) and insulinemia in healthy nondiabetic adult men. Diabetes Care 17:1135-1140
68. Haffner SM, Gruber KK, Morales PA, Hazuda HP, Valdez RA, Mitchell BD, Stern MP (1992) Lipoprotein(a) concentrations in Mexican Americans and non-Hispanic whites: the San Antonio Heart Study. Am J Epidemiol 136:1061-1068
69. Inoue K, Nago N, Matsuo H, Goto T, Miyamoto T, Saegusa T, Ishikawa S, Kario K, Nakamura Y, Igarashi M (1997) Serum insulin and lipoprotein(a) concentrations. Diabetes Care 20:1242-1247
70. Rainwater DL, Haffner SM (1998) Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations conrolled for LPA genotype. Arterioscler Thromb Vasc Biol 18:1335-1341
71. Emanuele N, Azad, N, Abraira C, Henderson W, Colwell J, Levin S, Nuttall F, Comstock J, Sawin C, Silbert C, Marcovina S, Sook Lee H (1998) Effect of intensive glycemic control on fibrinogen, lipids and lipoproteins. Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Arch Intern Med 158:2485-2490
72. Song KH, Ahn YB, Yoon KH, Cha BY, Lee KW, Son HY, Kang SK (1999) The effect of long-term glycaemic control on serum lipoprotein (a) levels in patients with type 2 diabetes mellitus. Diabet Med 16:1036-1039
73. Caixas A, Perez A, Qrdonez-llanos J, Bonet R, Rigla M, Castellvi A, Bayen L, de Leiva A (1997) Lack of change of lipoprotein(a) levels by the optimization of glycemic control with insulin therapy in NIDDM patients. Diabetes Care 20:1459-1461
74. Haffner SM, Tuttle KR, Rainwater DL (1991) Decrease of lipoprotein(a) with improved glycemic control in subjects with type II diabetes. Metabolism 41:116-120
75. Calmarza P, Vella JC (1999) Lipids, lipoproteins and apolipoprotein(a) isoforms in type 2 diabetic patients. J Cardiovasc Risk 6:171-175
76. Ribault A, Durou MR, Letellier C, Wojcik F, Poirier JY, Ruelland A (2000) Determination of lipoprotein(a) concentrations and apolipoprotein(a) molecular weights in diabetic patients. Diabetes Metab 2:107-112
77. Wolffenbuttel BH, Sels JP, Heesen BJ, Menheere PP, Nieuwenhuijzen-Kruseman AC (1992) Lipoprotein(a) levels and diabetes control. Diabetes Care 15:941
78. Simo R, Hernandez C, Chacon P, Marti R, Mesa J (1998) Effect of insulin administration on serum lipoprotein(a) and its phenotypes in new-onset IDDM patients. Diabetes Care 21:866-867
79. Bell DSH, Ovalle F (1998) Metformin lowers lipoprotein(a) levels. Diabetes Care 21:2028
80. Kiayias JA, Vlachou ED, Lakka Papadodima EL (1999) Metformin and lipoprotein(a) levels. Diabetes Care 22:859
81. Testa R, Bonfigli AR, Piantanelli L, Manfrini S, Testa I, Gregorio F (1996) Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 33:111-118
82. Landin K, Tengborn L, Smith U (1994) Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during hyperinsulinemic, euglycemic clamp in man. Thromb Haemost 71:783-787
83. Matsumato K, Miyake S, Yano M, Veki Y, Tominaya Y (1997) Increase of lipoprotein(a) with troglitazone. Lancet 350:1748-1749
84. Ovalle F, Bell DSH (1999) Troglitazone's effect on lipoprotein(a) levels. Diabetes Care 22:859-860
85. Matsumoto K, Miyake S, Yano M, Ueki Y, Tominaga Y (1999) Relationships between apolipoprotein(a) phenotype and increase of lipoprotein(a) by troglitazone. Metabolism 48:1-2
86. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T (1987) Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 30:144-148
87. Jarrett JR, Viberti GC, Argyropoulos A, Hill RD, Mahmud J, Murrells TJ (1984) Microalbuminuria predicts mortality in non-insulin dependent diabetes. Diabetic Med 1:17-19
88. Winocour P, Bhatnagar D, Ishola M, Arrol S, Durrington P (1991) Lipoprotein(a) and microvascular disease in type I (insulin-dependent) diabetes. Diabetic Med 8:922-927
89. Reverter JL, Senti M, Rubies-Prat J, Lucas A, Salinas I, Pizarro E, Pedro-Botet J, Romero R, Sanmarti A (1994) Relationship between lipoprotein profile and urinary albumin excretion in type II diabetic patients with stable metabolic control. Diabetes Care 17:189-194
90. Irish AB, Simons LA, Savdie E, Hayes JM, Simons J (1992) Lipoprotein(a) concentrations in chronic renal disease states, dialysis and transplantation. Aust N Z J Med 22:243-248
91. Haffner SM, Morales PA, Gruber MK, Hazuda HP, Stern MP (1993) Lack of association of lipids, lipoproteins, and Lp(a) with microalbuminuria in NIDDM. Arteriosclerosis 13:205-210
92. Jerums G, Allen TJ, Tsalamandris C, Akdeniz A, Sinka A, Gilbert R, Cooper ME (1993) Relationship of progressively increaseing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients. Diabetologia 36:1037-1044
93. Tarnow L, Rossing P, Nielsen FS, Hansen BV, Dyerberg J, Parving HH (1996) Increased plasma apolipoprotein(a) levels in IDDM patients with diabetic nephropathy. Diabetes Care 19:1382-1387
94. Hernandez C, Chacon P, Marti R, Garcia-Pascual L, Mesa J, Simo R (2000) Relationship of lipoprotein(a) and its phenotypes with the albumin excretion rate in diabetic patients: a multivariate analysis. Nephron 85:27-33
95. Thiery J, Ivandic B, Bahlmann G, Walli AK, Siedel D (1996) Hyperlipoprotein(a)aemia in nephrotic syndrome. Eur J Clin Invest 26:316-321
96. Boemi M, Sirolla C, Fumelli P, James RW (1999) Renal disease as a determinant of increased lipoprotein(a) concentrations in diabetic patients. Diabetes Care 22:2033-2036
97. Keilani T, Schlueter WA, Levin ML, Batlle DC (1993) Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 118:246-254
98. Sato H, Suzuki S, Ueno M (1993) Localization of apolipoprotein(a) and B-100 in various renal diseases. Kidney Int 43:430-435
99. Maser RE, Usher D, Becker DJ, Drash AL, Kuller LH, Orchard TJ (1993) Lipoprotein(a) concentration shows little relationship to IDDM complications in the Pittsburgh Epidemiology of Diabetes Complications Study Cohort. Diabetes Care 16:755-758
100. Pedreno J, Fernandez R, Ballester A, Jornet A, Uson M, Canela J, Petit M (2000) Lack of association of serum lipoprotein(a) levels with type-2 diabetes mellitus in patients with angiographically defined coronary artery disease. Int J Cardiol 74:159-167
101. Ruiz J, Thillet J, Huby Y, James RW, Erlich D, Flandre P, Froguel P, Chapman J, Passa P (1994) Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. Diabetologia 37:585-591
102. Hiraga T, Kobayashi Y, Okubo M, Nakanishi K, Sugimoto T, Ohashi Y, Murase T (1995) Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 18:241-244
103. James RW, Boemi M, Sirolla C, Amadio L, Fumelli P, Pometta D (1997) Lipoprotein(a) and vascular disease in diabetic patients. Diabetologia 38:711-714
104. Gazzaruso C, Gazaniti A, Falcone C, Geroldi D, Finardi G, Fratino P (2001) Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in type 2 diabetic patients and in non-diabetic subjects. Diabet Med 18:589-594
105. Watts GF, Gwilym R, Mazurkiewicz J, Coltart J (1995) Independent correlation between plasma lipoprotein(a) and angiographic coronary artery disease in NIDDM. Diabetes Care 18:234-236
106. Yamamoto M, Egusa G, Yamakido M (1997) Carotid atherosclerosis and serum lipoprotein(a) concentrations in patients with NIDDM. Diabetes Care 20:829-831
107. Wollesen F, Dahlen, G, Berglund L, Berne C (1999) Peripheral atherosclerosis and serum lipoprotein(a) in diabetes. Diabetes Care 22:93-98
108. Jenkins AJ, Steele JS, Janus ED, Best JD (1991) Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminura. Diabetes 40:787-790
109. Maioli M, Tonolo G, Pacifico A, Ciccarese M, Brizzi P, Kohner EM et al (1993) Raised serum apolipoprotein(a) in active diabetic retinopathy. Diabetologia 36:88-90
110. Gazzaruso C, Garzaniti A, Buscaglia P, D'Annunzio G, Porta A, Vandelli G, Lorini R, Finardi G, Fratino P, Geroldi D (1998) Lipoprotein(a) levels and apolipoprotein(a) polymorphism in type 1 diabetes mellitus: relationships to microvascular and neurological complications. Acta Diabetol 35:13-18
111. Kim CH, Park HJ, Park JY, Hong SK, Yoon YH, Lee KU (1998) High serum lipoprotein(a) levels in Korean type 2 diabetic patients with proliferative diabetic retinopathy. Diabetes Care 12:2149-2151
112. Doucet C, Huby T, Ruiz J, Chapman MJ, Thillet J (1995) Non-enzymatic glycation of lipoprotein(a) in vitro and in vivo. Atherosclerosis 118:135-143
113. Klaya F, Durlach V, Bertin E, Monier F, Monboisse JC, Gillery P (1997) Evaluation of serum glycated lipoprotein(a) levels in noninsulin-dependent diabetic patients. Clin Biochem 30:227-230
114. Makino K, Furbee JW, Scanu AM, Fless GM (1995) Effect of glycation on the properties of lipoprotein(a). Arterioscler Thromb Vasc Biol 15:385-391
115. Zhang J, Ren S, Shen GX (2000) Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells. Atherosclerosis 150:299-308